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INTRODUCTION 
Diabetes is a chronic disease, which occurs when the 
pancreas does not produce enough insulin, or when the 
body cannot effectively use the insulin it produces. This 
leads to an increased concentration of glucose in the blood 
(hyperglycaemia or Type 1 diabetes, previously known as 
insulin-dependent or childhood-onset diabetes) is 
characterized by a lack of insulin production. Type 2 
diabetes (formerly called non-insulin-dependent or adult-
onset diabetes) is caused by the body’s ineffective use of 
insulin. It often results from excess body weight and 
physical inactivity. Gestational diabetes is hyperglycemia 
that is first recognized during pregnancy. 
A total of 57 million deaths occurred in the world during 
2008; 36 million (63%) were due to NCDs, principally 
cardiovascular diseases, diabetes, cancer and chronic 
respiratory diseases. Nearly 80% of these NCD deaths (29 
million) occurred in low- and middle-income countries. 
NCDs are the most frequent causes of death in most 
countries in the Americas, the Eastern Mediterranean, 
Europe, South-East Asia, and the Western Paciﬁ c. In the 
African Region, there are still more deaths from infectious 
diseases than NCDs. Even there, however, the prevalence 
of NCDs is rising rapidly and is projected to cause almost 
three-quarters as many deaths as communicable, maternal, 
perinatal, and nutritional diseases by 2020, and to exceed 
them as the most common causes of death by 2030. WHO 
projections show that NCDs will be responsible for a 
signiﬁ cantly increased total number of deaths in the next 
decade. NCD deaths are projected to increase by 15% 
globally between 2010 and 2020 (to 44 million deaths).                                                                                                                    
Pioglitazone is a prescription drug of the class 
thiazolidinedione (TZD) with hypoglycemic action to treat 
diabetes. As Pioglitazone and Rosiglitazone are the same 
class of drugs, Rosiglitazone is already banned in India 
due to their cardiotoxcity activity causing MI 
Thiazolidinediones, such as pioglitazone, are synthetic 
ligands for peroxisome proliferator-activated receptors 
(PPARs). They alter the transcription of genes influencing 
carbohydrate and lipid metabolism, resulting in changed 
amounts of protein synthesis and, therefore, metabolic 
changes. Pioglitazone improves glycaemic control in 
people with Type 2 diabetes by improving insulin 
sensitivity through its action at PPAR gamma 1 and PPAR 
gamma 2, and affects lipid metabolism through action at 
PPAR alpha. The results of these interactions include 
increases in glucose transporters 1 and 4, decreased free 
fatty acids, enhanced insulin signalling, reduced tumour 
necrosis factor alpha (TNF alpha) and remodelling of 
adipose tissue. Together, these can increase glucose uptake 
and utilisation in the peripheral organs and decrease 
gluconeogenesis in the liver, thereby decreasing insulin 
resistance.                                                                               
The incidence of type 2 diabetes is at epidemic proportions 
throughout the world. Patients with diabetes have a 2–3 
fold increased risk of cardiovascular disease when 
compared to the general population. They also have a 
greatly increased risk for microvascular disease. Hence 
medications that successfully control hyperglycemia in 
type 2 diabetes patients are of utmost importance. The 
underlying primary pathology in type 2 diabetes is insulin 
resistance. Drugs that address insulin resistance are 
effective in controlling hyperglycemia. Thiazolidinediones 
(TZD) are one such class of drugs that work through 
PPAR gamma activation. Pioglitazone is a TZD which is 
widely used for treating patients with type 2 diabetes. 
Pioglitazone profile 
Cardiovascular safety  
There has been much discussion about the cardiovascular 
safety of TZDs over the last few years since the findings of 
a meta-analysis of 42 trials, in which Nissen et al 
compared the risk for MI associated with rosiglitazone 
with that of placebo or other antihyperglycemic agents. 
Rosiglitazone was associated with a significant 42% 
increased risk for MI.Since then several studies have 
shown some risk of increased myocardial infarction 
associated with rosiglitazone use. 
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Anti-inflammatory effects  
Thiazolidinediones have been shown to decrease post 
angioplasty neointimal hyperplasia in both animals and 
humans PPAR-γ ligands have been shown to inhibit and 
stimulate angiogenesis. Pioglitazone has been shown to 
have anti-proliferative effects in humans, decreasing in-
stent neointimal proliferation. 
Weight gain 
Pioglitazone causes dose-dependent and time-dependent 
weight gain alone and in combination with other 
hypoglycemic agents. The mechanism of weight gain is 
unclear but probably involves a combination of fluid 
retention and fat accumulation. 
Eeffects on liver 
There was no evidence of pioglitazone-induced 
hepatotoxicity or elevation of ALT levels in the pre-
approval clinical studies  
Edema 
It is unknown whether or not there is a causal relationship 
between pioglitazone and macular edema. Concern for 
TZD associated macular edema has risen due to multiple 
case reports.  
 Effect on skeletal system 
Thiazolidinediones have been associated with low bone 
density and increased fracture risk. A 4y observational 
study in older diabetic population showed that pioglitazone 
(and rosiglitazone) lowered bone density at trochanter, 
spine and whole body compared to those not taking 
TZDs.Separately pioglitazone has been shown to increase 
peripheral fractures in women compared to control groups 
(1.8 fracture vs. 1.15 per 100 patient years), but not in 
men, in the PROactive trial. Similar findings have been 
reported in other trials. There is insufficient data to suggest 
that pioglitazone increases risk of hip or spine fracture. 
Interactions studies 
In vivo drug-drug interaction studies have suggested that 
pioglitazone may be a weak inducer of CYP 450 isoform 3 
A4 substrate. An enzyme inhibitor of CYP2C8 (such as 
gemfibrozil) may significantly increase the AUC of 
pioglitazone and an enzyme inducer of CYP2C8 (such as 
rifampin) may significantly decrease the AUC of 
pioglitazone. Therefore, if an inhibitor or inducer of 
CYP2C8 is started or stopped during treatment with 
pioglitazone, changes in diabetes treatment may be needed 
based on clinical response. 
ADR 
Adverse effects of pioglitazone occurring in at least 5% of 
patients include upper respiratory tract infection, headache, 
sinusitis, myalgia, tooth disorder, aggravation of diabetes 
mellitus, and pharyngitis A postmarketing safety study of 
pioglitazone from 2008 showed that malaise and vomiting 
were the most frequently reported adverse reactions. Other 
adverse reactions included dizziness, headache, diarrhea, 
weight gain and abnormal liver function tests. 
Pioglitazone effectiveness: 
Prevention of type 2 diabetes 
TZDs have been shown to prevent the onset of type 2 
diabetes, which appears to be a class effect. Most recent 
data from Defronzo et al has shown that use of 
pioglitazone 45 mg reduced the incidence of type 2 
diabetes by around 62%.Separately rosiglitzone and 
troglitazone have also been shown to be effective in 
prevention of type 2 diabetes. It is plausible that this effect 
is mediated by preservation of beta cell function as shown 
in studies of pioglitazone and troglitazone in the 
prevention of type 2 diabetes in insulin resistance Hispanic 
women. 
Treatment of type 2 diabetes 
Pioglitazone is approved to be used as monotherapy or in 
combination with metformin, sulfonylurea or insulin. It has 
been shown to be moderately effective in achieving 
glycemic control in placebo-controlled studies of patients 
with type 2 diabetes, either as monotherapy or in 
combination with metformin, sulfonylurea or insulin. 
Scherbaum et al showed that pioglitazone, both 17.5 and 
35 mg/day, in addition to dietary control, was associated 
with significant reductions (vs. placebo) in mean levels of 
both glycosylated haemoglobin (HbA1C) and fasting 
blood glucose.  
Treatment of polycystic ovary syndrome 
Therapy with pioglitazone, like other thiazolidinediones, 
may result in ovulation in some premenopausal 
anovulatory women.As a result, these patients may be at an 
increased risk for pregnancy while taking pioglitazone. 
Thus, adequate contraception in premenopausal women 
should be recommended. 
Treatment of diabetic nephropathy (Effect on kidney) 
Small studies have suggested that TZDs may have 
protective effects on the kidney. A recent systematic 
review and meta-analysis comparing the use of TZDs 
(pioglitazone and rosiglitazone) to placebo or other anti-
diabetic agents concluded that thiazolidinedione treatment 
was associated with a significant decrease in urinary 
albumin clerearance. Limitations of this study included 
significant heterogeneity across included studies in several 
subgroup analyses and unavailable patient-level data. In a 
small 1-year open labeled randomized controlled trial of 
34 normoalbuminuric patients with type 2 diabetes, 
rosiglitazone appeared to exert nephroprotective effects 
beyond glycemic control.Future clinical trials looking into 
hard renal outcomes should be conducted to further 
delineate the potential benefits of thiazolidinediones on 
diabetic nephropathy. 
VITAMIN E                                                                                                                                                
It refers to a group of eight fat-soluble compounds that 
include both tocopherols and tocotrienols. Of the many 
different forms of vitamin E, γ-tocopherol is the most 
common in the North American diet. γ-Tocopherol can be 
found in corn oil, soybean oil, margarine, and dressings. In 
the North American diet, α-tocopherol, the most 
biologically active form of vitamin E, is the second-most 
common form of vitamin E. This variant can be found 
most abundantly in wheat germ oil, sunflower, and 
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safflower oils. As a fat-soluble antioxidant, it stops the 
production of reactive oxygen species formed when fat 
undergoes oxidation.  
Functions 
Vitamin E has many biological functions, the antioxidant 
function being the most important and/or best known other 
functions include enzymatic activities, gene expression, 
and neurological function(s). The most important function 
of vitamin E has been suggested to be in cell signaling 
(and it may not have a significant role in antioxidant 
metabolism) 
 As an antioxidant, vitamin E acts as a peroxyl 
radical scavenger, preventing the propagation of free 
radicals in tissues, by reacting with them to form a 
tocopheryl radical, which will then be reduced by a 
hydrogen donor (such as vitamin C) and thus return to 
its reduced state.[12] As it is fat-soluble, it is 
incorporated into cell membranes, which protects 
them from oxidative damage 
 Vitamin E also plays a role in neurological 
functions  and inhibition of platelet aggregation 
 As an enzymatic activity regulator, for instance, 
protein kinase C (PKC), which plays a role in smooth 
muscle growth, can be inhibited by α-tocopherol. α-
Tocopherol has a stimulatory effect on the 
dephosphorylation enzyme, protein phosphatase 2A, 
which in turn, cleaves phosphate groups from PKC, 
leading to its deactivation, bringing the smooth muscle 
growth to a halt 
 Vitamin E also protects lipids and prevents the 
oxidation of polyunsaturated fatty acids.  
So far, most human supplementation studies about vitamin 
E have used only α-tocopherol. This can affect levels of 
other forms of vitamin E, e.g. reducing serum γ- and δ-
tocopherol concentrations. Moreover, a 2007 clinical study 
involving α-tocopherol concluded supplementation did not 
reduce the risk of major cardiovascular events in middle-
aged and older me 
Deficiency 
Vitamin E deficiency can cause: 
 spinocerebellar ataxia 
 myopathies 
 peripheral neuropathy 
 ataxia 
 skeletal myopathy 
 retinopathy 
 impairment of the immune response 
 red blood cell destructio] Supplementation 
While vitamin E supplementation was initially hoped to 
have a positive effect on health, research has not supported 
this hope. Vitamin E does not decrease mortality in adults, 
even at large doses, and may slightly increase it. It does 
not improve blood sugar control in an unselected group of 
people with diabetes mellitus or decrease the risk of stroke. 
Daily supplementation of vitamin E does not decrease the 
risk of prostate cancer and may increase it. Studies on its 
role in age-related macular degeneration are ongoing as, 
though it is of a combination of dietary antioxidants used 
to treat the condition, it may increase the risk. A Japanese 
study in 2012 found vitamin E may contribute to 
osteoporosis. 
 Dietary sources 
Sunflower oil 
Safflower oil 
Nuts and nut oils, such as almonds and hazelnuts 
Palm oil 
High-value green, leafy vegetables: spinach, turnip, beet 
greens, collard greens, and  
One IU of vitamin E is defined as equivalent to either: 
0.67 mg of the natural form, RRR-α-tocopherol, also 
known as d-α-tocopherol; or 0.45 mg of the synthetic 
form, all-rac-α-tocopherol, also known as dl-α-
tocopherol.[6] 
 
Structure-Vitamin E 
MATERIALS AND METHOD 
Animals 
Wistar albino rats (150–200 g) were obtained from Central 
Animal Facility, Hamdard University and kept at 25±1 °C, 
55±5% humidity alongwith 12 h light/dark cycle. The 
animals were given standard pellet diet (Lipton rat feed, 
Ltd., Pune) and water ad libitum throughout the 
experimental period. The experiment was approved by the 
‘Institutional Animal Ethics Committee’. Both the drug 
pioglitazone and vitamin E were administered orally. 
36 Wistar rats of either sex is taken.It is divided into 6 
groups with 6 rats in each group.  
Animal will be kept overnight fasting, and drugs will be 
administered according to treatment schedule. 
Drug 
 
Trade name 
Doxorubicin Oncordia 
Pioglitazone Glit 
Vitamin E. Evion 
 
Statistical analysis 
Data are analyzed by  Post-Hock test & Dunnet test.
DOSAGE REGIMEN 
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Group Animal Rat No. of   
Animals 
Drug Treatment Dosage (mg/kg) rate of 
administration and duration 
Wt. (Kg) Age 
(Days) 
Strain 
1 150 55 Wistar albino rats 6 Control Nornal saline 0.9 % 
2 160 60 Wistar albino rats 6 Doxorubicin 15 mg/kg,I.P 
3 155 57 Wistar albino rats 6 Pioglitazone (Per se) 0.4 mg/kg,p.o 
4 165 65 Wistar albino rats 6 Vit. E(Per se) 0.15 mg/kg ,p.o 
5 170 70 Wistar albino rats 6 Doxorubicin + Pioglitazone 15 mg/kg,I.P+0.4 mg/kg,p.o 
6 163 64 Wistar albino rats 6 Doxorubicin + Pioglitazone + Vit. E 15 mg/kg,I.P+0.4 
mg/kg,p.o+0.15 mg/kg ,p.o 
 
RESULT 
Group of animal Drug administered LDL (mg/dl) HDL (mg/dl) Cholesterol (mg/dl) 
1 Normal Control Nornal saline 0.9 % 100  40  200  
2 Doxorubicin 15 mg/kg,I.P 120  30  240  
3 Pioglitazone (Per se) 0.4 mg/kg,p.o 110  35  220  
4 Vit. E(Per se) 0.15 mg/kg ,p.o 98  42  198  
5 Doxorubicin + 
Pioglitazone 
15 mg/kg,I.P+0.4 mg/kg,p.o 125  28  250  
6 Doxorubicin + 
Pioglitazone + Vit. E 
15 mg/kg,I.P+0.4 
mg/kg,p.o+0.15 mg/kg ,p.o 
105  36  199  
 
 
 
It is clear from the table and graph that the level of LDL 
cholesterol is significantly decreased in a group that is 
administered a combination of doxorubicin,pioglitazone 
and vitamin E,while it is moderate in group which is 
administerd with pioglitazone alone.Same events repeated 
with total cholesterol level.The events is reversed in HDL 
level i.e the group with triple combination have 
significantly higher level of HDL cholesterol in 
comparision to pioglitazone alone.Vitamin E treating 
group is still having highest level of HDL cholesterol.  
DISCUSSION 
Studies show that pioglitazone has anti-inflammatory, anti-
proliferative effects. But at  the same time pioglitazone 
also has proangiogenic and proliferative properties in 
certain situations. The overall  effect of the vascular effects 
of pioglitazone is likely tissue specific and depends on the 
pathophysiological process. E.g, its anti-proliferative, anti-
inflammatory effects effects may be beneficial in terms of 
decreasing post angioplasty restenosis or damage post-
stroke ischemia. These mechanisms may also be beneficial 
in the setting of NASH. However, its proangiogenic, 
proliferative properties exerted through VEGF, may be 
beneficial in wound healing in type 2 diabetes patients who 
lack adequate vascular supply to chronic wounds such as 
ulcers. Congestive heart failure may be one of the 
detrimental effects of pioglitazone mediated by a 
stimulation of VEGF expression. 
Weight gain is one of the main issues with pioglitazone 
treatment. This is may be  due to fluid gain as well as fat 
accumulation. However fat accumulation has been 
observed to be subcutaneous and not intra-abdominal. 
Moreover there may be a transfer of fat from the intra-
abdominal compartment to the subcutaneous compartment. 
This might lead to decreased cardiovascular risk as 
increased visceral fat is strongly linked to adverse 
cardiovascular outcomes. 
Newer detrimental effects on bone health and macular 
edema are yet to be characterized by perfectly  powered 
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and designed studies. Mechanisms by which these occur 
are not clear at this time.                      In terms of efficacy, 
along with vitamin E,overall reduction of insulin resistance 
and hyperglycemia shows that pioglitazone is clinically 
efficacious in type 2 diabetes. 
In conclusion current evident suggests that pioglitazone 
has an acceptable safety profile along with Vitamin E, may 
have beneficial cardiovascular and pleotropic effects and is 
efficacious in patients with type 2 diabetes. 
CONCLUSION 
It can be concluded from present study that pioglitazone 
alone if given to a potient of type 2 diabetes,it worsen 
cardiovascular complication of diabetes and it worsen lipid 
profiles by decreasing HDL and by increasing LDL 
cholesterol .Rosiglitazone,a member of thiozolidine dione 
is already withdrawn from market due to severe 
cardiovascular ADR. But when Pioglitazone is combined 
with Vitamin E,an antioxidant it reduces the complication 
and ADR,So by present study it can be deduced that 
combination of pioglitazone and Vitamin E is beneficial 
for diabetic patient regarding cardiovascular complication 
and other ADR. Drugs safety and efficay profile is 
increased and ADR profile is decreased along with vitamin 
E. 
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